ArticleMethods in molecular biology (Clifton, N.J.)2022
Exosome-related Methods and Potential Use as Vaccines.
Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- Article
- Exosome may be the next generation of promising cell-free vaccines.Human vaccines & immunotherapeutics · 2024Review
- Advances of exosomes in periodontitis treatment.Journal of translational medicine · 2022Review
- Biological Features of Extracellular Vesicles and Challenges.Frontiers in cell and developmental biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although significant clinical advances have been made in the treatment of cancer using the immune system, discovery of therapeutic cancer vaccines still remains as an area of interest. Development of the method of pulsing dendritic cells with tumor antigens set the stage for the development of cancer vaccines. Exosomes have gained significant interest because of their ability to activate dendritic cells to recognize and kill cancerous cells. Because of their characteristics such as superior biosafety profile to other nanoparticles, exosomes are promising nanocarriers for clinical use, which makes them an attractive candidate for cancer vaccine development. Identification of novel vaccinations for immunoprevention can be studied by exosomes. This chapter describes commonly used methods to isolate and manipulate exosomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.